News at CenExel

December 30, 2022

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal,...

December 28, 2022

Primer on the Autonomic Nervous System – 4th Edition

This book provides a concise and accessible overview of autonomic neuroscience for students, scientists, and clinicians.

November 3, 2022

CenExel Psychedelic Facilitators Undergoing Premier Certification Training

Our Clinical Sciences team, comprised of Dr. Larry Ereshefsky, Dr. Brett English, Dr. Robert Litman, along with Principal Investigators Dr. Djouher Hough, and Dr. Haig...

October 31, 2022

Placebo-Control Reminder Script

General medicine studies are not immune to the placebo effect, where 30-40% of patients report improved subjective and objective outcomes in general medical studies (Hrobjartsson &...

June 16, 2022

CenExel Acquires Apex Innovative Sciences

Salt Lake City, June 16, 2022 /GlobeNewswire/ — CenExel announces the acquisition of Apex Innovative Sciences, parent company of Collaborative Neuroscience Research (CNS) and Hassman...

April 19, 2021

CenExel Psychiatric Research Expert Presents Data at Schizophrenia International Research Society

Salt Lake City, Apr. 19, 2021 /PRNewswire/ — Robert E. Litman, MD, Founder and Medical Director at CBH Health (Gaithersburg, MD), a CenExel Clinical Research...